Tekla Capital Management’s Arena Pharmaceuticals Inc ARNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-175,976
| Closed | -$16.4M | – | 182 |
|
|
2021
Q4 | $16.4M | Buy |
175,976
+92,347
| +110% | +$6.08M | 0.53% | 48 |
|
|
2021
Q3 | $4.98M | Sell |
83,629
-112,756
| -57% | -$6.66M | 0.16% | 108 |
|
|
2021
Q2 | $13.4M | Hold |
196,385
| – | – | 0.44% | 59 |
|
|
2021
Q1 | $13.6M | Sell |
196,385
-56,586
| -22% | -$4.35M | 0.47% | 57 |
|
|
2020
Q4 | $19.4M | Buy |
252,971
+92,334
| +57% | +$6.92M | 0.68% | 40 |
|
|
2020
Q3 | $12M | Buy |
160,637
+72,635
| +83% | +$4.84M | 0.45% | 58 |
|
|
2020
Q2 | $5.54M | Buy |
88,002
+60,000
| +214% | +$3.3M | 0.21% | 96 |
|
|
2020
Q1 | $1.18M | Hold |
28,002
| – | – | 0.05% | 167 |
|
|
2019
Q4 | $1.27M | Hold |
28,002
| – | – | 0.05% | 174 |
|
|
2019
Q3 | $1.28M | Hold |
28,002
| – | – | 0.06% | 149 |
|
|
2019
Q2 | $1.64M | Sell |
28,002
-24,260
| -46% | -$1.25M | 0.07% | 140 |
|
|
2019
Q1 | $2.34M | Hold |
52,262
| – | – | 0.1% | 124 |
|
|
2018
Q4 | $2.04M | Sell |
52,262
-41,505
| -44% | -$1.63M | 0.09% | 130 |
|
|
2018
Q3 | $4.32M | Hold |
93,767
| – | – | 0.16% | 100 |
|
|
2018
Q2 | $4.09M | Buy |
93,767
+76,940
| +457% | +$3.31M | 0.16% | 104 |
|
|
2018
Q1 | $665K | Buy |
+16,827
| New | +$655K | 0.03% | 163 |
|
Tekla Capital Management's ARNA Position: Q1 2022 in Review
Tekla Capital Management sold out of Arena Pharmaceuticals Inc (ARNA) in Q1 2022, closing a stake of 175,976 shares — an estimated $16.4M sold.
Tekla Capital Management first reported a position in ARNA in Q1 2018 and held it in 16 quarters. The position peaked at $19.4M in Q4 2020. 1 fund tracked by Wall St. Rank holds ARNA as of Q1 2022.
- Tekla Capital Management reported no remaining Arena Pharmaceuticals Inc position as of Q1 2022 after selling out during the quarter.
- Tekla Capital Management sold 175,976 Arena Pharmaceuticals Inc shares in Q1 2022, an estimated $16.4M.
- Tekla Capital Management first reported a position in Arena Pharmaceuticals Inc in Q1 2018 and held it in 16 quarters.
- Tekla Capital Management's Arena Pharmaceuticals Inc position peaked at $19.4M in Q4 2020.
- 1 fund tracked by Wall St. Rank held Arena Pharmaceuticals Inc as of Q1 2022.
Based on Tekla Capital Management's 13F filing for Q1 2022, filed 13 May 2022.